BRPI0922806A2 - formas de dosagem oral de bendamustina - Google Patents

formas de dosagem oral de bendamustina

Info

Publication number
BRPI0922806A2
BRPI0922806A2 BRPI0922806A BRPI0922806A BRPI0922806A2 BR PI0922806 A2 BRPI0922806 A2 BR PI0922806A2 BR PI0922806 A BRPI0922806 A BR PI0922806A BR PI0922806 A BRPI0922806 A BR PI0922806A BR PI0922806 A2 BRPI0922806 A2 BR PI0922806A2
Authority
BR
Brazil
Prior art keywords
bendamustine
dosage forms
oral dosage
oral
forms
Prior art date
Application number
BRPI0922806A
Other languages
English (en)
Inventor
Jeffrey Colledge
Margaretha Olthoff
Original Assignee
Astellas Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40588059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0922806(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Deutschland Gmbh filed Critical Astellas Deutschland Gmbh
Publication of BRPI0922806A2 publication Critical patent/BRPI0922806A2/pt
Publication of BRPI0922806B1 publication Critical patent/BRPI0922806B1/pt
Publication of BRPI0922806B8 publication Critical patent/BRPI0922806B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4875Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0922806A 2008-12-03 2009-12-03 composição farmacêutica oral compreendendo bendamustina BRPI0922806B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08075915 2008-12-03
EP08075915.2 2008-12-03
PCT/EP2009/008857 WO2010063493A1 (en) 2008-12-03 2009-12-03 Oral dosage forms of bendamustine

Publications (3)

Publication Number Publication Date
BRPI0922806A2 true BRPI0922806A2 (pt) 2015-12-22
BRPI0922806B1 BRPI0922806B1 (pt) 2020-03-03
BRPI0922806B8 BRPI0922806B8 (pt) 2021-05-25

Family

ID=40588059

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922806A BRPI0922806B8 (pt) 2008-12-03 2009-12-03 composição farmacêutica oral compreendendo bendamustina

Country Status (25)

Country Link
US (4) US20120003305A1 (pt)
EP (1) EP2367542B1 (pt)
JP (1) JP5778037B2 (pt)
KR (1) KR101688038B1 (pt)
CN (2) CN105363037B (pt)
AU (1) AU2009321745B2 (pt)
BR (1) BRPI0922806B8 (pt)
CA (1) CA2745525A1 (pt)
CO (1) CO6400183A2 (pt)
CY (1) CY1114977T1 (pt)
DK (1) DK2367542T3 (pt)
EA (1) EA020354B1 (pt)
ES (1) ES2451540T3 (pt)
HR (1) HRP20140204T1 (pt)
IL (1) IL213270A (pt)
MX (1) MX2011005643A (pt)
NZ (1) NZ592970A (pt)
PL (1) PL2367542T3 (pt)
PT (1) PT2367542E (pt)
RS (1) RS53201B (pt)
SI (1) SI2367542T1 (pt)
SM (1) SMT201400053B (pt)
UA (1) UA102120C2 (pt)
WO (1) WO2010063493A1 (pt)
ZA (1) ZA201103791B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3587B1 (ar) * 2010-06-02 2020-07-05 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
CN102375044B (zh) * 2010-08-18 2015-04-08 重庆华邦胜凯制药有限公司 一种盐酸苯达莫司汀中间体z6有关物质的分析方法
EP2760842B1 (en) * 2011-09-26 2016-11-16 Fresenius Kabi Oncology Ltd An improved process for the preparation of bendamustine hydrochloride
ES2936387T3 (es) 2011-10-31 2023-03-16 Hoffmann La Roche Formulaciones de anticuerpos anti-il13
EP2641592A1 (en) 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
DK2656843T3 (en) 2012-04-26 2015-04-20 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof
KR20150086308A (ko) * 2012-11-12 2015-07-27 이그니타, 인코포레이티드 벤다무스틴 유도체 및 그의 사용 방법
ES2670995T3 (es) 2013-03-12 2018-06-04 Cephalon, Inc. Formulaciones de nanopartículas y macropartículas
JP2016153374A (ja) * 2013-06-25 2016-08-25 シンバイオ製薬株式会社 炎症性疾患を治療又は予防するための医薬組成物
EP3043648B1 (en) 2013-08-27 2023-09-20 Vasilios VOUDOURIS Bendamustine pharmaceutical compositions
RU2020115024A (ru) 2017-10-05 2021-11-08 Тьюб Фармасьютикалз Гмбх Препараты бендамустина для перорального введения

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US132502A (en) * 1872-10-22 Improvement in machines for removing snow from railroads
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
MX2007005361A (es) * 2004-11-05 2008-01-11 Cephalon Inc Tratamientos para cancer.
CN101052396A (zh) * 2004-11-05 2007-10-10 赛福伦公司 癌症治疗
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
UA94036C2 (ru) * 2005-01-14 2011-04-11 Сефалон, Инк. Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
CN101028249A (zh) * 2007-04-12 2007-09-05 济南康泉医药科技有限公司 一种含新生血管抑制剂及烷化剂的抗癌组合物
CN101045058A (zh) * 2007-04-28 2007-10-03 济南帅华医药科技有限公司 一种含烷化剂及激素类药物的抗癌组合物
CN101084876A (zh) * 2007-07-11 2007-12-12 济南康泉医药科技有限公司 一种含苯达莫司汀的抗癌组合物
US20090130198A1 (en) * 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders

Also Published As

Publication number Publication date
US10543196B2 (en) 2020-01-28
KR20110102393A (ko) 2011-09-16
JP2012510484A (ja) 2012-05-10
BRPI0922806B8 (pt) 2021-05-25
US20140018334A1 (en) 2014-01-16
AU2009321745B2 (en) 2016-06-23
CO6400183A2 (es) 2012-03-15
EP2367542A1 (en) 2011-09-28
CN102281871A (zh) 2011-12-14
SI2367542T1 (sl) 2014-05-30
EA201190011A1 (ru) 2012-02-28
CA2745525A1 (en) 2010-06-10
PL2367542T3 (pl) 2014-05-30
CN105363037A (zh) 2016-03-02
WO2010063493A1 (en) 2010-06-10
EP2367542B1 (en) 2014-01-01
RS53201B (sr) 2014-06-30
AU2009321745A1 (en) 2011-06-23
US20150335588A1 (en) 2015-11-26
DK2367542T3 (da) 2014-03-10
SMT201400053B (it) 2014-07-07
CN105363037B (zh) 2019-02-05
KR101688038B1 (ko) 2016-12-20
HRP20140204T1 (hr) 2014-04-11
EA020354B1 (ru) 2014-10-30
MX2011005643A (es) 2011-09-27
CY1114977T1 (el) 2016-12-14
BRPI0922806B1 (pt) 2020-03-03
PT2367542E (pt) 2014-03-10
NZ592970A (en) 2013-05-31
US20170095452A1 (en) 2017-04-06
ZA201103791B (en) 2012-07-25
IL213270A0 (en) 2011-07-31
ES2451540T3 (es) 2014-03-27
US20120003305A1 (en) 2012-01-05
JP5778037B2 (ja) 2015-09-16
IL213270A (en) 2017-05-29
UA102120C2 (ru) 2013-06-10

Similar Documents

Publication Publication Date Title
BRPI0922806A2 (pt) formas de dosagem oral de bendamustina
BRPI0922804A2 (pt) formas de dosagem sólidas de bendamustina
BRPI0921725A2 (pt) formas de dosagem potentes do tapentadol
EP2251005A4 (en) Orally disintegrating tablets
BRPI0920521A2 (pt) combinação farmacêutica
BRPI0810814A2 (pt) Formas sólidas de dosagem incluindo tadalafil
BRPI0912271A2 (pt) co-autoria estruturada
BRPI0920835A2 (pt) escova de dentes
BRPI1010739A2 (pt) formas de dosagens de apixaban.
BRPI1008023A2 (pt) forma de dosagem sólida
NO20083238L (no) Narresmokk
DK2381986T3 (da) Lægemiddeladministrationsanordning
BRPI0822884A2 (pt) Escova de dentes
BRPI0822906A2 (pt) Escova de dentes
IL234296B (en) Dosing regimen
EP2197448A4 (en) dosing schedule
BR112012031102A2 (pt) forma de dosagem oral sólida
BRPI0807882A2 (pt) Forma de dosagem
DK2271618T3 (da) Farmaceutiske forbindelser
SE0800657L (sv) Tandborste
IT1390848B1 (it) Composti farmaceutici
FR2939893B1 (fr) Dosage du plomb
UA18380S (uk) Перстень «ванесса»
UA17738S (uk) Зубна щітка
TH100876B (th) แปรงสีฟัน

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2803 DE 24-09-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.